Big Pharma and Orphan Drugs: The Case for Thinking Small

In this issue, The RPM Report looks at three advocates making three different but inter-related cases for greater involvement by Biopharma companies in research into rare diseases. Do they have any takers?

Michael McCaughan

It may be a paradox, but drugs to treat rare diseases are anything but rare. The Food & Drug Administration...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet